TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15040435

Group type: EXPERIMENTAL
Intervention: Educational programs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Support programs (telephone, in person, or both)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Written materials (pamphlets)
Number of subjects: 30
Study: 9820297

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interferon beta‐1a 22 microg
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interferon beta‐1a 44 microg
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 7711393

Group type: EXPERIMENTAL
Intervention: Heart Manual rehabilitation programme
Number of subjects: 34

Group type: COMPARATOR
Intervention: General advice and information booklets
Number of subjects: 34
Study: 2665546

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, L-asparaginase, and rubidomycin (Group B, n = 118)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Induction treatment with vincristine, prednisone, and L-asparaginase (Group A, n = 122)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 240
Study: 333084

Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg, 6 times per day for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, 6 times per day for 5 days
Number of subjects: 20
Study: 31483789

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham feedback (SF) group
Number of subjects: 33
Study: 28864319

Group type: EXPERIMENTAL
Intervention: CT group (ultrasound and CT results)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (transthoracic and transesophageal echocardiography data)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CT group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 25675557

Group type: EXPERIMENTAL
Intervention: Yin-yang meridians acupuncture with respiratory reinforcing and reducing manipulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Basic treatment (control group)
Number of subjects: 100
Study: 22471559

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19846007

Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (RM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (regular therapy only)
Number of subjects: 20
Study: 17509028

Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg once daily
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg once daily
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Alosetron (all groups)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg
Number of subjects: 705
Study: 14512295

Group type: EXPERIMENTAL
Intervention: Daunorubicin with standard dose of cytarabine
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Idarubicin with standard dose of cytarabine
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Mitoxantrone with standard dose of cytarabine
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 11673750

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily for 5 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study: 9826861

Group type: EXPERIMENTAL
Intervention: Endotak DSP lead
Number of subjects: 123

Group type: COMPARATOR
Intervention: Endotak C lead (Control)
Number of subjects: 123
Study: 7584300

Group type: EXPERIMENTAL
Intervention: Experienced children (those who had experienced events 8 months prior)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matched naive controls
Number of subjects: 21
Study: 2774052

Group type: EXPERIMENTAL
Intervention: Occupational Therapy Maternal Role Preparation Program (4 sessions)
Number of subjects: 16
Study: 891483

Group type: EXPERIMENTAL
Intervention: 0.5 mg glucagon (G)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 50 mg pethidine plus 0.5 mg atropine (PA)
Number of subjects: 30
Study: 31511036

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) with first-person perspective (1PP) during high-intensity intermittent aerobic exercise (HIE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immersive virtual reality (IVR) with third-person perspective (3PP) during high-intensity intermittent aerobic exercise (HIE)
Number of subjects: 30
Study: 28902334

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Triamcinolone
Number of subjects: 111
Study: 25185971

Group type: EXPERIMENTAL
Intervention: N‐IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly)
Number of subjects: 82

Group type: COMPARATOR
Intervention: IRI (irinotecan 150 mg/m2 biweekly)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: N‐IRI (EGFR 2+/3+)
Number of subjects: 82

Group type: COMPARATOR
Intervention: IRI (EGFR 2+/3+)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: N‐IRI
Number of subjects: 82

Group type: COMPARATOR
Intervention: IRI
Number of subjects: 82
Study: 23248249

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Daunorubicin (DNR)
Number of subjects: 727
Study: 21852581

Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 331

Group type: COMPARATOR
Intervention: High serum phosphate levels (highest two quartiles)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Phosphate as a continuous variable
Number of subjects: 331
Study: 19923789

Group type: EXPERIMENTAL
Intervention: Maternal plasma fibronectin levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AOPP levels in normotensive pregnant women
Number of subjects: 100

Group type: COMPARATOR
Intervention: AOPP levels in preeclamptic women
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for total fibronectin
Number of subjects: 100
Study: 16713439

Group type: EXPERIMENTAL
Intervention: voglibose (0.9 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 30
Study: 17152785

Group type: EXPERIMENTAL
Intervention: Long-term cardiac allograft valves after heart transplant
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Immunosuppressive/anti-inflammatory therapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Valvular regurgitation (grade ≥2)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cardiac function parameters
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Chamber dimensions
Number of subjects: 146
Study: 12691925

Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 10325851

Group type: EXPERIMENTAL
Intervention: Standard preformed tube
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Warmed preformed tube
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spiral-wound tracheal tubes (both designs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sharp tipped spiral tube
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Obtuse tipped spiral tube
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Manipulations after impaction
Number of subjects: 100
Study: 8556998

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1 after 45 s
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 after 45 s
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1 after 60 s
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 after 60 s
Number of subjects: 4
Study: 2202853

Group type: EXPERIMENTAL
Intervention: Nadolol (Corgard)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Anapriline
Number of subjects: 361

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 361

Group type: COMPARATOR
Intervention: Pratsiol
Number of subjects: 361
Study: 6104255

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined treatment with propranolol and prazosin
Number of subjects: 23
Study: 28945640

Group type: EXPERIMENTAL
Intervention: Ballistic Six upper‐extremity plyometric training in addition to the volleyball training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Volleyball training only
Number of subjects: 28
Study: 28742684

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 404

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 404
Study: 25752357

Group type: COMPARATOR
Intervention: 10-day hybrid regimen (PACT-10): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 10 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 5 days
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 14-day hybrid regimen (PACT-14): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 14 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 7 days
Number of subjects: 270
Study: 23298898

Group type: EXPERIMENTAL
Intervention: Combination of oral misoprostol and double‐balloon catheter
Number of subjects: 122

Group type: COMPARATOR
Intervention: Oral misoprostol alone
Number of subjects: 122
Study: 21310539

Group type: EXPERIMENTAL
Intervention: LETS ACT
Number of subjects: 58

Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 58
Study: 19370714

Group type: EXPERIMENTAL
Intervention: Staff education and training programme (8 weeks)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 306
Study: 17868728

Group type: EXPERIMENTAL
Intervention: Neovastat (shark cartilage extract AE 941)
Number of subjects: 300
Study: 15173148

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets
Number of subjects: 130000

Group type: COMPARATOR
Intervention: Former intervention households
Number of subjects: 130000
Study: 11317090

Group type: EXPERIMENTAL
Intervention: Aquatic exercise classes
Number of subjects: 249
Study: 8986678

Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose plus heparin (1,000 U/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose alone
Number of subjects: 40
Study: 8490772

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone injection along with oral placebo treatment (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone by a tapering schedule associated with placebo intramuscular injection (Group C)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intramuscular and oral placebos (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone injection (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone by a tapering schedule (Group C)
Number of subjects: 52
Study: 3814462

Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg p.o.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg s.l.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses)
Number of subjects: 11
Study: 31177482

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Counseling (CBC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Debriefing
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 193
Study: 28598701

Group type: EXPERIMENTAL
Intervention: Computerized cognitive exercises (SBT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tetris (active placebo)
Number of subjects: 18
Study: 25963350

Group type: EXPERIMENTAL
Intervention: Domestic leuprorelin acetate
Number of subjects: 236

Group type: COMPARATOR
Intervention: Imported leuprorelin acetate
Number of subjects: 236
Study: 23523158

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) in addition to medical therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed PTA after 6 months of medical therapy alone
Number of subjects: 15
Study: 21439044

Group type: EXPERIMENTAL
Intervention: BeWEL lifestyle programme (diet, physical activity and behaviour change)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 452
Study: 20109997

Group type: EXPERIMENTAL
Intervention: Trospium chloride 15 mg TID (up to 90 mg/d if needed)
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Oxybutynin hydrochloride 2.5 mg TID (up to 15 mg/d if needed)
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Trospium chloride
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Oxybutynin hydrochloride
Number of subjects: 1658
Study: 16424716

Group type: EXPERIMENTAL
Intervention: Novel repeated pulse treatment with methylprednisolone (1 g/day for 3 days) and cyclophosphamide (15 mg/kg/day for 2 days), followed by dexamethasone 20 mg/day until Pao2 was >11.5 kPa, and repeated pulse therapy if Pao2 was <8.64 kPa
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 23
Study: 15241610

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11835041

Group type: EXPERIMENTAL
Intervention: Lumen-centered gamma or beta radiation source
Number of subjects: 28

Group type: COMPARATOR
Intervention: Noncentered source position
Number of subjects: 28
Study: 9578184

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All three proton pump inhibitors
Number of subjects: 14
Study: 7865644

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (75 mg, 300 mg, enteric coated 300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plain aspirin 75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2475678

Group type: EXPERIMENTAL
Intervention: Chronic verapamil treatment
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 444
Study: 770079

Group type: EXPERIMENTAL
Intervention: Azapropazone 1200 mg per day before food
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31899977

Group type: EXPERIMENTAL
Intervention: Perispinal etanercept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 31864376

Group type: EXPERIMENTAL
Intervention: Pre-referral treatment with rectal artesunate
Number of subjects: 387
Study: 28103444

Group type: EXPERIMENTAL
Intervention: simoctocog alfa (Nuwiq)
Number of subjects: 0
Study: 25727114

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for anxiety disorders
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual care for anxiety disorders
Number of subjects: 1004
Study: 23548832

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus Virtual Reality Exposure Therapy (VRET)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus Exposure in Vivo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 55
Study: 21741331

Group type: EXPERIMENTAL
Intervention: 4g/L of ascites removed (group 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 8g/L of ascites removed (group 2)
Number of subjects: 70
Study: 19201586

Group type: EXPERIMENTAL
Intervention: Magnesium citrate 300 mg/day for 5 weeks (group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 32
Study: 16636211

Group type: EXPERIMENTAL
Intervention: Weight loss and exercise therapy (6 months of weekly behavioral therapy for weight loss + exercise training 3 times per week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Weight loss and exercise therapy
Number of subjects: 27
Study: 15499509

Group type: EXPERIMENTAL
Intervention: Disease management programme (DMP) based on weekly telephone monitoring by a case manager
Number of subjects: 115
Study: 11092233

Group type: EXPERIMENTAL
Intervention: New weight-reducing agent based on natural ingredients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9091835

Group type: EXPERIMENTAL
Intervention: Seaprose S (30 mg tablets, 90 mg daily for 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Serratio-peptidase (5 mg tablets, 30 mg daily for 14 days)
Number of subjects: 40
Study: 1334101

Group type: EXPERIMENTAL
Intervention: Oat bran (10.3 g beta-glucan/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 36
Study: 6418295

Group type: COMPARATOR
Intervention: Energy reduced diet (5.1 MJ; 1230 kcal) with unchanged sodium intake (1:ErSn)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Energy and sodium restricted diet (5.1 MJ; 1220 kcal) (2:ErSr)
Number of subjects: 30
Study: 29939897

Group type: EXPERIMENTAL
Intervention: Warm-up and apneas (WUAP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Apneas only (AP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Warm-up only (WU)
Number of subjects: 9
Study: 31607020

Group type: EXPERIMENTAL
Intervention: Vertebral artery stent implantation via radial artery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vertebral artery stent implantation via femoral artery
Number of subjects: 24
Study: 28646860

Group type: EXPERIMENTAL
Intervention: Exercise plus Social Cognitive Theory (SCT) education
Number of subjects: 65

Group type: COMPARATOR
Intervention: Exercise plus attention control education
Number of subjects: 65
Study: 25647168

Group type: EXPERIMENTAL
Intervention: Intervention group received a $110 voucher for smoking cessation pharmacotherapy and were registered to an automated calling system.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group received standard care including smoking cessation advice, a brochure, and a prescription for smoking cessation medication if requested.
Number of subjects: 90
Study: 24029535

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioural therapy (telephone CBT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 99
Study: 21631542

Group type: EXPERIMENTAL
Intervention: gabapentin and flumazenil combination
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebos
Number of subjects: 60
Study: 19483295

Group type: EXPERIMENTAL
Intervention: Routine dosage fosinopril (10 mg once daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Middle dosage fosinopril (10 mg twice a day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study: 16920648

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 33
Study: 16419683

Group type: EXPERIMENTAL
Intervention: Ultra-high-frequency masking with the UltraQuiet device
Number of subjects: 15
Study: 10639191

Group type: EXPERIMENTAL
Intervention: Finasteride (5alpha-reductase inhibitor) for 6 days to 6 years
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9253234

Group type: EXPERIMENTAL
Intervention: Clinical data used to build a predictive model based on 21 variables including age, absence of previous similar episodes, weight loss, rectal bleeding, lack of improvement, and presence of a mass on digital rectal examination.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Clinical data from one subgroup compared with the other subgroup using Bayes' theorem.
Number of subjects: 336
Study: 1534881

Group type: EXPERIMENTAL
Intervention: Second-look laparoscopy with lysis of adhesions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 40
Study: 3896216

Group type: EXPERIMENTAL
Intervention: diltiazem (360 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 3064885

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31837959

Group type: EXPERIMENTAL
Intervention: Alisertib (30 mg orally twice per day on days 8-15) combined with 7+3 induction chemotherapy (continuous infusion of cytarabine 100 mg/m2 per day on days 1-7 and intravenous bolus of idarubicin 12 mg/m2 per day on days 1-3)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alisertib maintenance for 12 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: 7+3 induction chemotherapy (cytarabine and idarubicin)
Number of subjects: 39
Study: 29735965

Group type: EXPERIMENTAL
Intervention: Mild moxibustion at bilateral Shenshu (BL23) for 15 min daily, for 4 courses (5 days each with 2 days between courses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin E soft capsules for 28 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 60
Study: 28079918

Group type: EXPERIMENTAL
Intervention: Lamivudine daily oral dose 60-300 mg (3.9-17.6 mg kg-1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lamivudine daily oral dose 8-10 mg kg-1 day-1 for children <14 kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Bodyweight as a covariate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: External evaluation of the pharmacokinetic model
Number of subjects: 180
Study: 26169067

Group type: EXPERIMENTAL
Intervention: Active Team Facebook app (n=51 individuals, 12 teams)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Wait-listed control condition (n=59 individuals, 13 teams)
Number of subjects: 110